Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case

Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treating JIA under pediatric indications. Clinical Case Des...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ekaterina V. Denisova, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Margarita A. Soloshenko, Anna V. Mamutova, Kseniya B. Isayeva, Anna N. Fetisova
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	"Paediatrician" Publishers LLC 2018-10-01
Edice:	Вопросы современной педиатрии
Témata:	children juvenile idiopathic arthritis genetically engineered biological preparations golimumab infliximab
On-line přístup:	https://vsp.spr-journal.ru/jour/article/view/1931
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!